Finance

Lists
Q2 2026 earnings • released • EPS miss -55.00% • Revenue beat +1.42%
See results
CTKB:NASDAQ
Cytek Biosciences Inc
$4.38
+4.40%
(+0.19) 1D
Aug 10, 2:18:06 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CTKB...
Open
$4.32
High
$4.38
Low
$4.16
Mkt. cap
569.98M
Avg. vol.
926.85K
Volume
350.88K
52-wk high
$6.18
52-wk low
$3.28
EPS
-$0.63
Beta
1.17
Shares outstanding
129.98M
No. of employees
682
Open
$4.32
High
$4.38
Low
$4.16
Mkt. cap
569.98M
Avg. vol.
926.85K
Volume
350.88K
52-wk high
$6.18
52-wk low
$3.28
EPS
-$0.63
Beta
1.17
Shares outstanding
129.98M
No. of employees
682
About Cytek Biosciences Inc
CEO-
Employees682
Founded1992
Headquarters-
SectorHealth care
Websitecytekbio.com
Analyst ratings
Based on 4 analysts giving stock ratings to CTKB in the past 3 months
Buy
Buy
2
Hold
2
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CTKB in the last 3 months.
Highest
Current $4.38
$7.50 (+71.04%)
Average
$5.56 (+26.80%)
Lowest
$4.75 (+8.32%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kallum Titchmarsh
Morgan Stanley
Hold
Maintained
$5.00
+14%
08/06/2026
David Westenberg
Piper Sandler
Buy
Reiterated
$7.50
+71%
08/06/2026
Brendan Smith
TD Cowen
Hold
Maintained
$5.00
+14%
08/05/2026
Mason Carrico
Stephens
Buy
Reiterated
$4.75
+8.3%
05/13/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.03 / -$0.02
-55.00%miss
Revenue / Est. (USD)
48.14M / 47.46M
+1.42%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
52.29M
62.14M
44.14M
48.14M
Cost of goods sold
24.74M
29.26M
22.88M
22.60M
Cost of revenue
24.74M
29.26M
22.88M
22.60M
Research and development expenses
8.96M
8.96M
9.60M
9.74M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27.79M
29.52M
30.11M
30.00M
Operating expense
36.74M
38.48M
39.72M
39.74M
Total operating expenses
61.48M
67.74M
62.60M
62.34M
Operating income
-9.19M
-5.59M
-18.46M
-14.20M
Other non operating income
444.00K
1.56M
1.76M
1.52M
EBT including unusual items
-7.77M
-4.03M
-17.37M
-11.64M
EBT excluding unusual items
-7.77M
-4.03M
-17.37M
-12.84M
Income tax expense
-2.29M
40.04M
1.49M
515.00K
Effective tax rate
29.49%
-993.43%
-8.59%
-4.42%
Other operating expenses
-
-
-
-
Net income
-5.48M
-44.08M
-18.87M
-12.16M
Net profit margin
-10.48%
-70.93%
-42.75%
-25.26%
Earnings per share
-0.00
-0.29
-0.10
-0.03
Interest and investment income
573.00K
1.30M
787.00K
819.00K
Interest expense
-494.00K
-
-262.00K
-281.00K
Net interest expenses
79.00K
1.30M
525.00K
538.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-7.27M
-3.70M
-16.60M
-12.19M
Gain or loss from assets sale
102.00K
60.00K
55.00K
138.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps